1. Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.
- Author
-
Shu S, Wu HJ, Ge JY, Zeid R, Harris IS, Jovanović B, Murphy K, Wang B, Qiu X, Endress JE, Reyes J, Lim K, Font-Tello A, Syamala S, Xiao T, Reddy Chilamakuri CS, Papachristou EK, D'Santos C, Anand J, Hinohara K, Li W, McDonald TO, Luoma A, Modiste RJ, Nguyen QD, Michel B, Cejas P, Kadoch C, Jaffe JD, Wucherpfennig KW, Qi J, Liu XS, Long H, Brown M, Carroll JS, Brugge JS, Bradner J, Michor F, and Polyak K
- Subjects
- Animals, Antineoplastic Agents pharmacology, Azepines pharmacology, Cell Cycle Proteins metabolism, Cell Line, Tumor, Chromosomal Proteins, Non-Histone metabolism, Female, Gene Expression Regulation, Neoplastic drug effects, Humans, Mice, Mice, Inbred NOD, Nuclear Proteins metabolism, Proteins metabolism, Signal Transduction drug effects, Transcription Factors metabolism, Triazoles pharmacology, Triple Negative Breast Neoplasms genetics, Triple Negative Breast Neoplasms metabolism, Drug Resistance, Neoplasm genetics, Proteins antagonists & inhibitors, Triple Negative Breast Neoplasms drug therapy
- Abstract
BET bromodomain inhibitors (BBDIs) are candidate therapeutic agents for triple-negative breast cancer (TNBC) and other cancer types, but inherent and acquired resistance to BBDIs limits their potential clinical use. Using CRISPR and small-molecule inhibitor screens combined with comprehensive molecular profiling of BBDI response and resistance, we identified synthetic lethal interactions with BBDIs and genes that, when deleted, confer resistance. We observed synergy with regulators of cell cycle progression, YAP, AXL, and SRC signaling, and chemotherapeutic agents. We also uncovered functional similarities and differences among BRD2, BRD4, and BRD7. Although deletion of BRD2 enhances sensitivity to BBDIs, BRD7 loss leads to gain of TEAD-YAP chromatin binding and luminal features associated with BBDI resistance. Single-cell RNA-seq, ATAC-seq, and cellular barcoding analysis of BBDI responses in sensitive and resistant cell lines highlight significant heterogeneity among samples and demonstrate that BBDI resistance can be pre-existing or acquired., Competing Interests: Declaration of Interests M.B. and K.P. received research support and were consultants to the Novartis Institutes for BioMedical Research during the execution of this study. K.P. serves on the scientific advisory board of Farcast Biosciences and Acrivon Therapeutics. M.B. receives sponsored research support from Novartis, serves on the SAB of Kronos Bio, and is a consultant to GTx, Inc., Aleta Biotherapeutics, and H3 Biomedicine. R.Z. and J.B. are current employees of C4 Therapeutics Inc. and Novartis, respectively. C.K. is a scientific founder, fiduciary board of directors member, scientific advisory board member, consultant, and shareholder of Foghorn Therapeutics, Inc. (Cambridge, MA). S. Shu, K.P., and J.B. are inventors of a patent on BET inhibitor resistance that DFCI licensed to Roche., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF